|Study Description:||The goal of this clinical research study is to learn if dabrafenib or the |
combination of dabrafenib and trametinib can help to control thyroid cancer
that has a mutation or fusion in the BRAF gene. The safety of these drugs will
also be studied.
Dabrafenib is designed to block the mutated BRAF protein. By blocking the
protein, the drug may slow the growth of or kill cancer cells that have the
Trametinib is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die.